#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687

#EULAR2025 Abstr#OP0265 Do we have convenient biomarkers to help predict new ANA+ referral who would progress to #SLE #Sjogren at 12 mths? Proteomics analysis identified IFN and B-cell markers. Validation is needed and to incorporate clinical items into prognostic model @RheumNow https://t.co/TWClLTKQ0b

#EULAR2025 Abstr#POS0318 Single timepoint assessment may not show true picture of #SLE control. Data from BILAG-BR registry using machine learning showed 6 trajectories with clinical meaning: -Nonresponse with high activity: dsDNA-ve & RNP+ -Response-flare: active MSK @RheumNow https://t.co/VrI8e4ONtM

#WIN in systemic sclerosis (SSc): -Ongoing trials now targeting multiple pathways. -CONQUEST platform may reshape research in Ssc and other autoimmune diseases. -Revised CRISS could replace single organ endpoints for approval. #EULAR2025 @RheumNow https://t.co/kxSeFb5lAU

+RCT in #pSjD #Sjogrens #Disease #Leflunomide + #hydroxychloroquine Vs #PBO 2nd study to show this - same group need to know ▶️what pt to use this in ▶️is there diff organ improvements ⬆️#ESSDAI ⬇️RF ⬇️Ig’s Easy to prescribe ?early, mild dx #EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6

#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow

In BIODOPT study (RA, PsA, axSpA), disease activity-guided tapering of biologics (incl. biosimilars) maintained QALY (Δ0.008, NS) while lowering biologic costs (Δ€–1,979 [95%CI –3,798;–161]) & total hospital costs (Δ€–1,936 [95%CI –3,753;–119]) over 18mo. Supports https://t.co/CJUpfU2oRA

What ‘CAR’ to drive? #CAR-T buzz was at #EULAR2025 In multiple #rheumatic #diseases #SLE #Scleroderma #Sjogrens #myositis Even #axial #SpA Who - active, not a lot of damage Which target 🎯 Which priming regiment What will results be compared to? Who will pay? @RheumNow

APEX study showed significant inhibition of structural damage progression with both dosing regimens (Q4W and Q8W) of GUS (IL-23i) in biologic-naïve pts with active PsA. Abstract #LB0010 #EULAR2025 @RheumNow https://t.co/QxYAPGB67v

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.